Literature DB >> 9552388

The family of polo-like kinases.

R M Golsteyn1, H A Lane, K E Mundt, L Arnaud, E A Nigg.   

Abstract

Here we discuss members of a new family of serine/threonine protein kinases with a likely role in cell cycle control. These kinases are referred to as polo-like kinases, after the prototypic founding member of the family, the polo gene product of Drosophila melanogaster. The polo kinase was originally identified in mutants that display abnormal mitotic spindle organization. Subsequently, potential homologues of Drosophila polo have been identified in yeasts (Cdc5p in Saccharomyces cerevisiae; plo1+ in Schizosaccharmoyces pombe) and in mammals (polo-like kinase 1; Plk1). Genetic and biochemical studies suggest that polo, Cdc5p and plo1+ may be required for mitotic spindle organization and, possibly, for cytokinesis. Likewise, the patterns of expression, activity and subcellular localization of Plk1 strongly suggest that this mammalian kinase functions also during mitosis, possibly in spindle assembly and function. In addition to Plk1, however, more distantly related members of the polo-like kinase family have been identified in mammalian cells, and the available data are consistent with the idea that some of these may act earlier in the cell cycle, possibly during G1. If this hypothesis is correct, different members of the polo-like kinase family would act at several points during the cell cycle, reminiscent of the behaviour of Cdk/cyclin complexes.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9552388     DOI: 10.1007/978-1-4615-5873-6_11

Source DB:  PubMed          Journal:  Prog Cell Cycle Res        ISSN: 1087-2957


  17 in total

1.  The disappearance of cyclin B at the end of mitosis is regulated spatially in Drosophila cells.

Authors:  J Huang; J W Raff
Journal:  EMBO J       Date:  1999-04-15       Impact factor: 11.598

2.  An oncoinformatics study to predict the inhibitory potential of recent FDA-approved anti-cancer drugs against human Polo-like kinase 1 enzyme: a step towards dual-target cancer medication.

Authors:  Syed Mohd Danish Rizvi; Abdulaziz Arif A Alshammari; Waleed Abdullah Almawkaa; Abo Bakr F Ahmed; Ahmed Katamesh; Ahmed Alafnan; Tariq J Almutairi; Rakan F Alshammari
Journal:  3 Biotech       Date:  2019-02-09       Impact factor: 2.406

3.  Increased human polo-like kinase-1 expression in gliomas.

Authors:  K Dietzmann; E Kirches; K Jachau; C Mawrin
Journal:  J Neurooncol       Date:  2001-05       Impact factor: 4.130

4.  Inhibitory effect of Polo-like kinase 1 depletion on mitosis and apoptosis of gastric cancer cells.

Authors:  Xue-Hua Chen; Bin Lan; Ying Qu; Xiao-Qing Zhang; Qu Cai; Bing-Ya Liu; Zheng-Gang Zhu
Journal:  World J Gastroenterol       Date:  2006-01-07       Impact factor: 5.742

5.  The DDR-related gene signature with cell cycle checkpoint function predicts prognosis, immune activity, and chemoradiotherapy response in lung adenocarcinoma.

Authors:  Quan Li; Pan Zhang; Huixiao Hu; Hang Huang; Dong Pan; Guangyun Mao; Burong Hu
Journal:  Respir Res       Date:  2022-07-15

6.  Role of Plk2 (Snk) in mouse development and cell proliferation.

Authors:  Sheng Ma; Jean Charron; Raymond L Erikson
Journal:  Mol Cell Biol       Date:  2003-10       Impact factor: 4.272

7.  The scaffold protein TANK/I-TRAF inhibits NF-kappaB activation by recruiting polo-like kinase 1.

Authors:  Wanqiao Zhang; Jian Wang; Ying Zhang; Yanzhi Yuan; Wei Guan; Chaozhi Jin; Hui Chen; Xiaohui Wang; Xiaoming Yang; Fuchu He
Journal:  Mol Biol Cell       Date:  2010-05-19       Impact factor: 4.138

Review 8.  Regulation of Cdc28 cyclin-dependent protein kinase activity during the cell cycle of the yeast Saccharomyces cerevisiae.

Authors:  M D Mendenhall; A E Hodge
Journal:  Microbiol Mol Biol Rev       Date:  1998-12       Impact factor: 11.056

9.  Plx1 is required for chromosomal DNA replication under stressful conditions.

Authors:  Kristina Trenz; Alessia Errico; Vincenzo Costanzo
Journal:  EMBO J       Date:  2008-02-28       Impact factor: 11.598

Review 10.  Targeting the cell cycle for cancer therapy.

Authors:  A Carnero
Journal:  Br J Cancer       Date:  2002-07-15       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.